IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy

Basirudeen S. Kabeer, Alamelu Raja, Balambal Raman, Satheesh Thangaraj, Marc Leportier, Giuseppe Ippolito, Enrico Girardi, Philippe H. Lagrange, Delia Goletti

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background: There is an urgent need of prognosis markers for tuberculosis (TB) to improve treatment strategies. The results of several studies show that the Interferon (IFN)-γ-specific response to the TB antigens of the QuantiFERON TB Gold (QFT-IT antigens) decreases after successful TB therapy. The objective of this study was to evaluate whether there are factors other than IFN-γ [such as IFN-γ inducible protein (IP)-10 which has also been associated with TB] in response to QFT-IT antigens that can be used as biomarkers for monitoring TB treatment.Methods: In this exploratory study we assessed the changes in IP-10 secretion in response to QFT-IT antigens and RD1 peptides selected by computational analysis in 17 patients with active TB at the time of diagnosis and after 6 months of treatment. The IFN-γ response to QFT-IT antigens and RD1 selected peptides was evaluated as a control. A non-parametric Wilcoxon signed-rank test for paired comparisons was used to compare the continuous variables at the time of diagnosis and at therapy completion. A Chi-square test was used to compare proportions.Results: We did not observe significant IP-10 changes in whole blood from either NIL or QFT-IT antigen tubes, after 1-day stimulation, between baseline and therapy completion (p = 0.08 and p = 0.7 respectively). Conversely, the level of IP-10 release to RD1 selected peptides was significantly different (p = 0.006). Similar results were obtained when we detected the IFN-γ in response to the QFT-IT antigens (p = 0.06) and RD1 selected peptides (p = 0.0003). The proportion of the IP-10 responders to the QFT-IT antigens did not significantly change between baseline and therapy completion (p = 0.6), whereas it significantly changed in response to RD1 selected peptides (p = 0.002). The proportion of IFN-γ responders between baseline and therapy completion was not significant for QFT-IT antigens (p = 0.2), whereas it was significant for the RD1 selected peptides (p = 0.002), confirming previous observations.Conclusions: Our preliminary study provides an interesting hypothesis: IP-10 response to RD1 selected peptides (similar to IFN-γ) might be a useful biomarker for monitoring therapy efficacy in patients with active TB. However, further studies in larger cohorts are needed to confirm the consistency of these study results.

Original languageEnglish
Article number135
JournalBMC Infectious Diseases
Volume11
DOIs
Publication statusPublished - 19 May 2011
Externally publishedYes

Fingerprint

Tuberculosis
Biomarkers
Antigens
Interferons
Peptides
Proteins
Therapeutics
Chemokine CXCL10
Matched-Pair Analysis
Chi-Square Distribution
Nonparametric Statistics
Gold

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. / Kabeer, Basirudeen S.; Raja, Alamelu; Raman, Balambal; Thangaraj, Satheesh; Leportier, Marc; Ippolito, Giuseppe; Girardi, Enrico; Lagrange, Philippe H.; Goletti, Delia.

In: BMC Infectious Diseases, Vol. 11, 135, 19.05.2011.

Research output: Contribution to journalArticle

Kabeer, BS, Raja, A, Raman, B, Thangaraj, S, Leportier, M, Ippolito, G, Girardi, E, Lagrange, PH & Goletti, D 2011, 'IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy', BMC Infectious Diseases, vol. 11, 135. https://doi.org/10.1186/1471-2334-11-135
Kabeer, Basirudeen S. ; Raja, Alamelu ; Raman, Balambal ; Thangaraj, Satheesh ; Leportier, Marc ; Ippolito, Giuseppe ; Girardi, Enrico ; Lagrange, Philippe H. ; Goletti, Delia. / IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. In: BMC Infectious Diseases. 2011 ; Vol. 11.
@article{5582f251e9e94724a9ce89b352945cb9,
title = "IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy",
abstract = "Background: There is an urgent need of prognosis markers for tuberculosis (TB) to improve treatment strategies. The results of several studies show that the Interferon (IFN)-γ-specific response to the TB antigens of the QuantiFERON TB Gold (QFT-IT antigens) decreases after successful TB therapy. The objective of this study was to evaluate whether there are factors other than IFN-γ [such as IFN-γ inducible protein (IP)-10 which has also been associated with TB] in response to QFT-IT antigens that can be used as biomarkers for monitoring TB treatment.Methods: In this exploratory study we assessed the changes in IP-10 secretion in response to QFT-IT antigens and RD1 peptides selected by computational analysis in 17 patients with active TB at the time of diagnosis and after 6 months of treatment. The IFN-γ response to QFT-IT antigens and RD1 selected peptides was evaluated as a control. A non-parametric Wilcoxon signed-rank test for paired comparisons was used to compare the continuous variables at the time of diagnosis and at therapy completion. A Chi-square test was used to compare proportions.Results: We did not observe significant IP-10 changes in whole blood from either NIL or QFT-IT antigen tubes, after 1-day stimulation, between baseline and therapy completion (p = 0.08 and p = 0.7 respectively). Conversely, the level of IP-10 release to RD1 selected peptides was significantly different (p = 0.006). Similar results were obtained when we detected the IFN-γ in response to the QFT-IT antigens (p = 0.06) and RD1 selected peptides (p = 0.0003). The proportion of the IP-10 responders to the QFT-IT antigens did not significantly change between baseline and therapy completion (p = 0.6), whereas it significantly changed in response to RD1 selected peptides (p = 0.002). The proportion of IFN-γ responders between baseline and therapy completion was not significant for QFT-IT antigens (p = 0.2), whereas it was significant for the RD1 selected peptides (p = 0.002), confirming previous observations.Conclusions: Our preliminary study provides an interesting hypothesis: IP-10 response to RD1 selected peptides (similar to IFN-γ) might be a useful biomarker for monitoring therapy efficacy in patients with active TB. However, further studies in larger cohorts are needed to confirm the consistency of these study results.",
author = "Kabeer, {Basirudeen S.} and Alamelu Raja and Balambal Raman and Satheesh Thangaraj and Marc Leportier and Giuseppe Ippolito and Enrico Girardi and Lagrange, {Philippe H.} and Delia Goletti",
year = "2011",
month = "5",
day = "19",
doi = "10.1186/1471-2334-11-135",
language = "English",
volume = "11",
journal = "BMC Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central",

}

TY - JOUR

T1 - IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy

AU - Kabeer, Basirudeen S.

AU - Raja, Alamelu

AU - Raman, Balambal

AU - Thangaraj, Satheesh

AU - Leportier, Marc

AU - Ippolito, Giuseppe

AU - Girardi, Enrico

AU - Lagrange, Philippe H.

AU - Goletti, Delia

PY - 2011/5/19

Y1 - 2011/5/19

N2 - Background: There is an urgent need of prognosis markers for tuberculosis (TB) to improve treatment strategies. The results of several studies show that the Interferon (IFN)-γ-specific response to the TB antigens of the QuantiFERON TB Gold (QFT-IT antigens) decreases after successful TB therapy. The objective of this study was to evaluate whether there are factors other than IFN-γ [such as IFN-γ inducible protein (IP)-10 which has also been associated with TB] in response to QFT-IT antigens that can be used as biomarkers for monitoring TB treatment.Methods: In this exploratory study we assessed the changes in IP-10 secretion in response to QFT-IT antigens and RD1 peptides selected by computational analysis in 17 patients with active TB at the time of diagnosis and after 6 months of treatment. The IFN-γ response to QFT-IT antigens and RD1 selected peptides was evaluated as a control. A non-parametric Wilcoxon signed-rank test for paired comparisons was used to compare the continuous variables at the time of diagnosis and at therapy completion. A Chi-square test was used to compare proportions.Results: We did not observe significant IP-10 changes in whole blood from either NIL or QFT-IT antigen tubes, after 1-day stimulation, between baseline and therapy completion (p = 0.08 and p = 0.7 respectively). Conversely, the level of IP-10 release to RD1 selected peptides was significantly different (p = 0.006). Similar results were obtained when we detected the IFN-γ in response to the QFT-IT antigens (p = 0.06) and RD1 selected peptides (p = 0.0003). The proportion of the IP-10 responders to the QFT-IT antigens did not significantly change between baseline and therapy completion (p = 0.6), whereas it significantly changed in response to RD1 selected peptides (p = 0.002). The proportion of IFN-γ responders between baseline and therapy completion was not significant for QFT-IT antigens (p = 0.2), whereas it was significant for the RD1 selected peptides (p = 0.002), confirming previous observations.Conclusions: Our preliminary study provides an interesting hypothesis: IP-10 response to RD1 selected peptides (similar to IFN-γ) might be a useful biomarker for monitoring therapy efficacy in patients with active TB. However, further studies in larger cohorts are needed to confirm the consistency of these study results.

AB - Background: There is an urgent need of prognosis markers for tuberculosis (TB) to improve treatment strategies. The results of several studies show that the Interferon (IFN)-γ-specific response to the TB antigens of the QuantiFERON TB Gold (QFT-IT antigens) decreases after successful TB therapy. The objective of this study was to evaluate whether there are factors other than IFN-γ [such as IFN-γ inducible protein (IP)-10 which has also been associated with TB] in response to QFT-IT antigens that can be used as biomarkers for monitoring TB treatment.Methods: In this exploratory study we assessed the changes in IP-10 secretion in response to QFT-IT antigens and RD1 peptides selected by computational analysis in 17 patients with active TB at the time of diagnosis and after 6 months of treatment. The IFN-γ response to QFT-IT antigens and RD1 selected peptides was evaluated as a control. A non-parametric Wilcoxon signed-rank test for paired comparisons was used to compare the continuous variables at the time of diagnosis and at therapy completion. A Chi-square test was used to compare proportions.Results: We did not observe significant IP-10 changes in whole blood from either NIL or QFT-IT antigen tubes, after 1-day stimulation, between baseline and therapy completion (p = 0.08 and p = 0.7 respectively). Conversely, the level of IP-10 release to RD1 selected peptides was significantly different (p = 0.006). Similar results were obtained when we detected the IFN-γ in response to the QFT-IT antigens (p = 0.06) and RD1 selected peptides (p = 0.0003). The proportion of the IP-10 responders to the QFT-IT antigens did not significantly change between baseline and therapy completion (p = 0.6), whereas it significantly changed in response to RD1 selected peptides (p = 0.002). The proportion of IFN-γ responders between baseline and therapy completion was not significant for QFT-IT antigens (p = 0.2), whereas it was significant for the RD1 selected peptides (p = 0.002), confirming previous observations.Conclusions: Our preliminary study provides an interesting hypothesis: IP-10 response to RD1 selected peptides (similar to IFN-γ) might be a useful biomarker for monitoring therapy efficacy in patients with active TB. However, further studies in larger cohorts are needed to confirm the consistency of these study results.

UR - http://www.scopus.com/inward/record.url?scp=79959497508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959497508&partnerID=8YFLogxK

U2 - 10.1186/1471-2334-11-135

DO - 10.1186/1471-2334-11-135

M3 - Article

VL - 11

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

SN - 1471-2334

M1 - 135

ER -